Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Dec 2, 2009

Premium

ShanghaiBio announced the appointment of Michael Lutz as its advisor for ongoing global corporate development activities. Lutz was formerly senior VP of pharmacogenetics partnerships for Clinical Data's PGxHealth division and global general manager of the company's Cogenics division.


Pathway Genomics has appointed Sidney Stolz as its new chief growth officer, responsible for expanding Pathway's direct-to-consumer genetic testing services.

Before coming to Pathway, Stolz was executive VP of Healthcare Solutions. He has also held various executive positions at Towers Perrin and UnitedHealth Group. In 1997, Stolz became the CEO of UHG's global consulting division.


Exagen Diagnostics announced the appointment of Scott Glenn as its new CEO and chairman of its board of directors. Glenn replaces interim CEO Waneta Tuttle.

Prior to joining Exagen, Glenn was managing partner of Windamere Venture Partners and founded several biomedical companies, including Prometheus Laboratories, Santarus, Dexcom, among others. Before joining Windamere Ventures, Glenn was president and CEO of Quidel and held various positions with Allergan Pharmaceuticals.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.